Go to the list of all blogs
Allana's Avatar
published in Blogs
Mar 07, 2023
Kala Pharmaceuticals (KALA, $22.34 ) Q4 earnings miss estimates

Kala Pharmaceuticals (KALA, $22.34 ) Q4 earnings miss estimates

Kala Pharmaceuticals (KALA) recently reported its fourth-quarter earnings, which missed estimates, causing some concern among investors. The company reported a loss of $0.32 per share, missing the consensus estimate of a loss of $0.29 per share. Despite the miss, the company's revenue beat expectations, coming in at $14.6 million compared to the expected $13.8 million.

The Q4 earnings miss is certainly a cause for concern, but it's important to consider the larger picture when evaluating KALA as an investment opportunity. One positive sign for the company is the recent crossover of its 50-day moving average above its 200-day moving average on February 17, 2023. This technical indicator, known as a "golden cross," is a bullish signal that suggests the stock is shifting to an upward trend.

Moving averages are commonly used by technical analysts to identify trends and potential buy/sell signals. The 50-day moving average is a short-term trend indicator, while the 200-day moving average is a long-term trend indicator. When the 50-day moving average crosses above the 200-day moving average, it suggests that the stock is gaining momentum and could continue to rise in the future.

Overall, Kala Pharmaceuticals' Q4 earnings miss is undoubtedly noteworthy, but it's crucial to consider more than just one quarter's worth of data. Recent golden crosses for the company are possibly bullish signs that might point to a longer-term higher trend for the stock.

Related Ticker: KALA

Momentum Indicator for KALA turns negative, indicating new downward trend

KALA saw its Momentum Indicator move below the 0 level on June 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 73 similar instances where the indicator turned negative. In of the 73 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for KALA turned negative on July 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KALA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for KALA entered a downward trend on June 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where KALA advanced for three days, in of 201 cases, the price rose further within the following month. The odds of a continued upward trend are .

KALA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.402) is normal, around the industry mean (22.980). P/E Ratio (0.000) is within average values for comparable stocks, (38.292). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.534). KALA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (0.000) is also within normal values, averaging (407.380).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. KALA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KALA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 126.5B. VRTX holds the highest valuation in this group at 126.5B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 4%. For the same Industry, the average monthly price growth was 15%, and the average quarterly price growth was 1,818%. CRNX experienced the highest price growth at 116%, while CRIS experienced the biggest fall at -97%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was -26% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 80
Price Growth Rating: 52
SMR Rating: 94
Profit Risk Rating: 92
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
KALA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of ophthalmic treatments based on its mucosal penetrating product platform

Industry Biotechnology

Profile
Details
Industry
Pharmaceuticals Major
Address
1167 Massachusetts Avenue
Phone
+1 781 996-5252
Employees
6
Web
https://www.kalarx.com
Interact to see
Advertisement
Aon plc (AON) reported third-quarter 2025 revenue of $3.997 billion, representing a 7% year-over-year increase with equal organic growth. Adjusted earnings per share came in at $3.05, exceeding expectations. In late November, Moody’s reaffirmed Aon’s Baa2 credit rating and revised the outlook to positive, citing reduced leverage following the NFP acquisition.
Air Products and Chemicals, Inc. (APD) entered the spotlight after announcing advanced discussions with Yara International on December 8 to collaborate on low-emission ammonia projects. While the strategic direction aligns with global decarbonization trends, uncertainty around execution and capital requirements triggered a 9.45% one-day decline in the stock.
Lockheed Martin and RTX Corporation are two of the most prominent names in the aerospace and defense industry, both positioned to benefit from heightened global security concerns and sustained U.S. military spending.
As 2025 winds down, the Savings Banks sector reflects a mix of stability, innovation, and AI-driven disruption. Among the most closely watched tickers—SOFI Technologies (SOFI), Ally Financial (ALLY), and PayPal Holdings (PYPL)—investors have witnessed contrasting stories of growth, valuation, and market perception.
Ondas Holdings (ONDS) is a wireless technology company focused on delivering secure, long-range communications for industrial Internet of Things (IoT) and data networking applications. Its solutions are built to support mission-critical operations across sectors such as rail, energy, maritime, infrastructure, and industrial automation.
Ciena’s growth is driven by expanding offerings in optical networking, network automation software, and 5G transport infrastructure, complemented by services designed to help customers modernize and future-proof their networks. Its evolving technology portfolio addresses the rising complexity, speed, and reliability requirements of today’s communications environment.
Marathon Digital Holdings (MARA) and Riot Platforms (RIOT) are two leading companies in the Bitcoin mining industry, each operating energy-intensive infrastructure to capitalize on cryptocurrency market cycles. This comparison is especially relevant amid ongoing Bitcoin price volatility and growing interest in digital assets and AI-related infrastructure.
Roivant Sciences has delivered strong year-to-date performance, with shares up roughly 82%, driven by encouraging pipeline developments and increased investment in high-potential subsidiaries such as Immunovant.
MP Materials Corp. (MP) and USA Rare Earth, Inc. (USAR) are central to the United States’ push to establish a secure, domestic supply of rare earth elements—materials critical to electric vehicles, renewable energy, and defense technologies. As geopolitical tensions and supply chain vulnerabilities intensify, these two companies offer distinct approaches to addressing U.S. dependence on foreign sources.
The Invesco QQQ Trust (NASDAQ: QQQ) remains one of the most closely followed ETFs worldwide, offering investors direct exposure to the NASDAQ-100 Index®. In the most recent data, QQQ has gained a notable +20.16% year-to-date, even as markets experienced bouts of elevated volatility.
Pioneer Power's 2025 highlights include the expansion of its mobile power and charging footprint with new orders and partnerships; the launch of a new suite of e-Boost solutions for off-grid EV charging; the rebranding of HomeBoost as PowerCore with events in December; the introduction of PRYMUS in December; and a new five-year contract for network transformers with a regional utility provider.
An AI-driven comparison between Palantir (PLTR) and Oracle (ORCL) points to Palantir as the more compelling investment heading into 2026. The analysis highlights PLTR’s AI-native platforms, which enable real-time, data-driven decision-making across fast-growing sectors such as government, defense, and enterprise analytics.
An AI-driven comparison between D-Wave Quantum (QBTS) and IonQ (IONQ) points to IonQ as the stronger opportunity heading into 2026. The analysis highlights IONQ’s gate-based, trapped-ion quantum architecture, which supports a wide range of algorithms and positions the company for broader adoption across AI, simulation, and cryptography.
An AI-driven comparison of Rigetti Computing (RGTI) and D-Wave Quantum (QBTS) points to Rigetti as the more compelling opportunity heading into 2026. The analysis highlights RGTI’s gate-based quantum architecture, which supports universal quantum computing and a wide range of complex algorithms. While D-Wave remains a leader in quantum annealing for optimization problems, Rigetti’s full-stack, gate-based approach offers greater scalability and broader long-term applications.
An AI-driven comparison of Rigetti Computing (RGTI) and TeraWulf (WULF) points to TeraWulf as the more attractive investment heading into 2026. The analysis emphasizes WULF’s large-scale digital infrastructure supporting Bitcoin mining and high-performance computing (HPC), which generates immediate revenue in expanding digital asset and AI-driven markets.
An AI-driven comparison between Rocket Lab USA (RKLB) and Planet Labs (PL) identifies Rocket Lab as the more compelling investment heading into 2026. The analysis highlights RKLB’s vertically integrated space services and consistent launch performance, which position the company to benefit from rising demand for satellite deployment and space infrastructure.
An AI-driven comparison of Tempus AI (TEM) and Doximity (DOCS) points to Tempus AI as the more compelling investment opportunity heading into 2026. The analysis highlights TEM’s AI-powered precision medicine platform, which applies advanced analytics and genomic data to transform diagnostics and treatment in oncology and cardiology.
An AI-driven comparison of UnitedHealth Group (UNH) and CVS Health (CVS) points to UnitedHealth as the stronger investment heading into 2026. The analysis emphasizes UNH’s deeply integrated healthcare model, combining insurance, data analytics, pharmacy services, and care delivery into a single ecosystem. This structure provides resilience and earnings stability in an increasingly complex healthcare environment.
An AI-driven comparison of Netflix (NFLX) and Disney (DIS) points to Netflix as the more attractive investment heading into 2026. The analysis emphasizes Netflix’s focused, pure-play streaming model and its continued investment in original content, which support strong subscriber engagement as viewing habits shift further toward digital platforms.